In an open-label phase III trial (METRIC), 322 patients with BRAF V600E/K-mutant MM were randomized to receive either trametinib (n = 214) or chemotherapy with either dacarbazine or paclitaxel (n = 108) [63]. The gene discussed is BRAF; the disease is Miyoshi myopathy.